{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:57:26Z","timestamp":1793120246129,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1208\/s12248-021-00632-7","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T16:33:17Z","timestamp":1630427597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin"],"prefix":"10.1208","volume":"23","author":[{"given":"Asha J","family":"Kapetas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Y","family":"Abuhelwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A David","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"issue":"21","key":"632_CR1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR. Drug metabolism and variability among patients in drug response. The New England journal of medicine. 2005;352(21):2211\u201321.","journal-title":"The New England journal of medicine."},{"issue":"5","key":"632_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1568026013395001","volume":"1","author":"Z Yan","year":"2001","unstructured":"Yan Z, Caldwell GW. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Current topics in medicinal chemistry. 2001;1(5):403\u201325.","journal-title":"Current topics in medicinal chemistry."},{"issue":"7","key":"632_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","volume":"14","author":"MJ Waring","year":"2015","unstructured":"Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery. 2015;14(7):475\u201386.","journal-title":"Nature Reviews Drug Discovery."},{"key":"632_CR4","unstructured":"FDA. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020."},{"key":"632_CR5","unstructured":"EMA. Guideline on the investigation of drug interactions. 2012."},{"issue":"5","key":"632_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie\u201d. Drug metabolism and disposition: the biological fate of chemicals. 2006;34(5):880\u20136.","journal-title":"Drug metabolism and disposition: the biological fate of chemicals."},{"issue":"3","key":"632_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.967","volume":"104","author":"M Drozdzik","year":"2018","unstructured":"Drozdzik M, Busch D, Lapczuk J, Muller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2018;104(3):515\u201324.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"632_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & therapeutics. 2013;138(1):103\u201341.","journal-title":"Pharmacology & therapeutics."},{"issue":"10","key":"632_CR9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced drug delivery reviews. 2002;54(10):1271\u201394.","journal-title":"Advanced drug delivery reviews."},{"issue":"6","key":"632_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/cpt.1328","volume":"105","author":"D Rodrigues","year":"2019","unstructured":"Rodrigues D, Rowland A. From endogenous compounds as biomarkers to plasma-derived nanovesicles as liquid biopsy; has the golden age of translational pharmacokinetics-absorption, distribution, metabolism, excretion-drug-drug interaction science finally arrived? Clinical Pharmacology & Therapeutics. 2019;105(6):1407\u201320.","journal-title":"Clinical Pharmacology & Therapeutics."},{"issue":"1","key":"632_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bcp.13793","volume":"85","author":"A Rowland","year":"2019","unstructured":"Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood L, Meech R, et al. Plasma extracellular nanovesicle (exosome) derived biomarkers for ADME pathways: a novel approach to characterise variability in drug exposure. Br J Clin Pharmacol. 2019;85(1):216\u201326.","journal-title":"Br J Clin Pharmacol."},{"key":"632_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/cpt.2244","volume":"110","author":"A Rodrigues","year":"2021","unstructured":"Rodrigues A, van Dyk M, Sorich M, Fahmy A, Useckaite Z, Newman L, et al. Serum-derived extracellular vesicles as liquid biopsy to study the induction of hepatic cytochromes P450 and organic anion transporting polypeptides. Clin Pharmacol Ther. 2021;110:248\u201358.","journal-title":"Clin Pharmacol Ther."},{"key":"632_CR13","doi-asserted-by":"crossref","unstructured":"van Dyk M, Kapetas AJ, Hopkins AM, Rodrigues AD, Vourvahis M, Sorich MJ, et al. Validation of a 3-h sampling interval to assess variability in cytochrome P450 3A phenotype and the impact of induction and mechanism-based inhibition using midazolam as a probe substrate. Frontiers in Pharmacology. 2019;10(1120).","DOI":"10.3389\/fphar.2019.01120"},{"issue":"3","key":"632_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","volume":"44","author":"S Zhou","year":"2005","unstructured":"Zhou S, Chan SY, Goh BC, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics. 2005;44(3):279\u2013304.","journal-title":"Clinical Pharmacokinetics."},{"issue":"5","key":"632_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","volume":"21","author":"AJ Kapetas","year":"2019","unstructured":"Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A. Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction. The AAPS journal. 2019;21(5):78.","journal-title":"The AAPS journal."},{"issue":"5","key":"632_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010;39(5):298\u2013309.","journal-title":"Eur J Pharm Sci."},{"issue":"1","key":"632_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1208\/s12248-020-00541-1","volume":"23","author":"S Badaoui","year":"2021","unstructured":"Badaoui S, Hopkins AM, Rodrigues AD, Miners JO, Sorich MJ, Rowland A. Application of model informed precision dosing to address the impact of pregnancy stage and CYP2D6 phenotype on foetal morphine exposure. The AAPS Journal. 2021;23(1):15.","journal-title":"The AAPS Journal."},{"issue":"6","key":"632_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/psp4.46","volume":"4","author":"AM Hopkins","year":"2015","unstructured":"Hopkins AM, Wiese MD, Proudman SM, O\u2019Doherty CE, Foster D, Upton RN. Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):362\u201371.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"6","key":"632_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/cpt.1076","volume":"104","author":"A Rowland","year":"2018","unstructured":"Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ. Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clinical pharmacology and therapeutics. 2018;104(6):1219\u201328.","journal-title":"Clinical pharmacology and therapeutics."},{"issue":"6","key":"632_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/jcph.1377","volume":"59","author":"MJ Sorich","year":"2019","unstructured":"Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, et al. Use of physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in axitinib exposure: a fresh approach to precision dosing in oncology. Journal of clinical pharmacology. 2019;59(6):872\u20139.","journal-title":"Journal of clinical pharmacology."},{"issue":"3","key":"632_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00228-012-1339-x","volume":"69","author":"SK Quinney","year":"2013","unstructured":"Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SD. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. European journal of clinical pharmacology. 2013;69(3):439\u201348.","journal-title":"European journal of clinical pharmacology."},{"issue":"1","key":"632_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12916-018-1154-z","volume":"16","author":"AM Hopkins","year":"2018","unstructured":"Hopkins AM, Rowland A, Sorich MJ. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability. BMC medicine. 2018;16(1):165.","journal-title":"BMC medicine."},{"issue":"2","key":"632_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/dmd.109.028746","volume":"38","author":"SK Quinney","year":"2010","unstructured":"Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metabolism and Disposition. 2010;38(2):241\u20138.","journal-title":"Drug Metabolism and Disposition."},{"issue":"12","key":"632_CR24","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1086\/508873","volume":"43","author":"EJC Goldstein","year":"2006","unstructured":"Goldstein EJC, Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clinical Infectious Diseases. 2006;43(12):1603\u201311.","journal-title":"Clinical Infectious Diseases."},{"issue":"1","key":"632_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin pharmacokinet. 2000;38(1):41\u201357.","journal-title":"Clin pharmacokinet."},{"issue":"10","key":"632_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","volume":"64","author":"RC Owens Jr","year":"2004","unstructured":"Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64(10):1091\u2013124.","journal-title":"Drugs."},{"issue":"5","key":"632_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0009-9236(98)90137-0","volume":"64","author":"AD van Haarst","year":"1998","unstructured":"van Haarst AD, van\u2019t Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998;64(5):542\u20136.","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"632_CR28","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1124\/dmd.114.058404","volume":"42","author":"AS Darwich","year":"2014","unstructured":"Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug metabolism and disposition: the biological fate of chemicals. 2014;42(12):2016\u201322.","journal-title":"Drug metabolism and disposition: the biological fate of chemicals."},{"issue":"6","key":"632_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clinical pharmacology and therapeutics. 2019;105(6):1345\u201361.","journal-title":"Clinical pharmacology and therapeutics."},{"issue":"10","key":"632_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1124\/dmd.118.081364","volume":"46","author":"L Prieto Garcia","year":"2018","unstructured":"Prieto Garcia L, Janz\u00e9n D, Kanebratt KP, Ericsson H, Lennern\u00e4s H, Lundahl A. Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predictions and the mechanistic understanding of CYP3A4 drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals. 2018;46(10):1420\u201333.","journal-title":"Drug metabolism and disposition: the biological fate of chemicals."},{"issue":"3","key":"632_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","volume":"43","author":"K Rowland Yeo","year":"2011","unstructured":"Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci. 2011;43(3):160\u201373.","journal-title":"Eur J Pharm Sci."},{"key":"632_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fphar.2016.00517","volume":"7","author":"A Rowland","year":"2016","unstructured":"Rowland A, Mangoni AA, Hopkins A, Sorich MJ, Rowland A. Optimized cocktail phenotyping study protocol using physiological based pharmacokinetic modeling. Front Pharmacol. 2016;7:517.","journal-title":"Front Pharmacol."},{"key":"632_CR33","doi-asserted-by":"crossref","unstructured":"Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2017:10.1111\/bcp.13478.","DOI":"10.1111\/bcp.13478"},{"issue":"2","key":"632_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5414\/CPP38053","volume":"38","author":"JA Johnson","year":"2000","unstructured":"Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. International journal of clinical pharmacology and therapeutics. 2000;38(2):53\u201360.","journal-title":"International journal of clinical pharmacology and therapeutics."},{"issue":"2","key":"632_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0006-2952(92)90010-G","volume":"44","author":"CM Hunt","year":"1992","unstructured":"Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochemical pharmacology. 1992;44(2):275\u201383.","journal-title":"Biochemical pharmacology."},{"issue":"6","key":"632_CR36","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/cpt.1433","volume":"105","author":"K Venkatakrishnan","year":"2019","unstructured":"Venkatakrishnan K, Rostami-Hodjegan A. Come dance with me: transformative changes in the science and practice of drug-drug interactions. Clinical pharmacology and therapeutics. 2019;105(6):1272\u20138.","journal-title":"Clinical pharmacology and therapeutics."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00632-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:33:42Z","timestamp":1632778422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00632-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00632-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D.R. is an employee and stockholder of Pfizer Inc. A.R. and M.J.S. are recipients of unrelated research support from Pfizer Inc. All authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"104"}}